Threshold halting enrollment in clinical trial

Redwood City biopharmaceutical firm Threshold Pharmaceuticals Inc. (THLD) will stop enrollment in a Phase 2 clinical trial evaluating the use of glufosfamide in patients with recurrent, sensitive small cell lung cancer.

The first stage of the trial, which included 21 patients, showed only one confirmed partial response. Under the design of the trial, three or more responses were required before an additional 29 patients would have been enrolled.

Patients already enrolled will be given the option to continue in the trial.

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

SF police union calls for federal prosecution of man shot by police

San Francisco’s police union on Monday said it would ask federal authorities… Continue reading

Market Street goes car-free Wednesday — but can the new law be enforced?

Officials say simple rule will keep autos off SF’s main artery

At 2020 Grammys, new stars bail out the old-boys-club academy

Billie Eilish, 18, wins album, record and song of the year honors

Kobe Bryant, daughter Gianna among 9 dead in helicopter crash

Kobe Bryant, 41, the legendary basketball star who spent 20 years with… Continue reading

Don’t confuse exhaustion with lack of political might

2020 San Francisco Women’s March proves inspirational

Most Read